Table 3 Risk factor analysis of overall survival in tumor tissue

Age (<60/≥60)

0.704 (0.250–1.983)

0.507

Gender (female/male)

0.263 (0.034–2.007)

0.197

HBsAg (no/yes)

1.688 (0.379–7.521)

0.492

HBV-DNA replication(no/yes)

1.491 (0.539–4.122)

0.441

Liver cirrhosis (no/yes)

1.117 (0.355–3.515)

0.850

Preoperative AFP (<20/≥20 ng/ml)

0.741 (0.262–2.100)

0.573

Preoperative AFP (<400/≥400 ng/ml)

1.033 (0.351–3.035)

0.954

Tumor number (1/>1)

0.861 (0.251–3.174)

0.893

Tumor size (<5/≥5 cm)

1.304 (0.462–3.677)

0.616

Tumor size (<8/≥8 cm)

2.193 (0.729–6.594)

0.162

PV or VI invasion (no/yes)

0.959 (0.268–3.433)

0.949

PVTT (no/yes)

0.517 (0.067–3.973)

0.526

Lymph node metastasis (no/yes)

0.773 (0.098–6.077)

0.807

Intrahepatic metastasis (no/yes)

1.264 (0.429–3.726)

0.670

Liver capsular invasion (no/yes)

5.811 (1.975–17.096)

0.001

7.206 (1.571–33.063)

0.011

TNM stage (I/II–IV)

2.322 (0.772–6.980)

0.134

Differentiation (well/moderate or poor)

1.529 (0.541–4.318)

0.423

TACE (no/yes)

0.877 (0.276–2.794)

0.825

MFN2 expression (low/high)

0.263 (0.074–0.933)

0.039

0.063 (0.008–0.496)

0.009